On the Comparison of Two HBV Recombinant Vaccines

We would like to call your attention to our conviction that for a fair and balanced judgment of the article “Comparison of Two Recombinant Hepatitis B Vaccines” by Hasan Nikui Nejad et al. (1) published in your journal, the readers should consider a number of drawbacks, which in our opinion cast serious doubts upon the validity of the conduction, methods and conclusions of that trial. In this regard we judge it essential to take into account the following observations: In order to ensure that vaccines used in national immunization services in different countries are safe and effective and to avoid having to constantly demonstrate the validity of vaccines, the World Health Organization (WHO) has compiled a list (2) of the available and proven vaccines it recommends for purchase by the United Nations (UN) agencies, without making any distinction between them (3). The present comparison seems either untimely, or the reason for it unclear or undisclosed, since both vaccines are included in this list.